Vimarsana
Biggest News Aggregation in the World

Page 21 - Immunic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immunic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immunic Today - Breaking & Trending Today

Brokerages Anticipate Immunic, Inc. (NASDAQ:IMUX) Will Post Earnings of -$0.76 Per Share - Vimarsana News

Brokerages Anticipate Immunic, Inc. (NASDAQ:IMUX) Will Post Earnings of -$0.76 Per Share

Wall Street brokerages expect Immunic, Inc. (NASDAQ:IMUX – Get Rating) to post earnings per share of ($0.76) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Immunic’s earnings, with estimates ranging from ($0.93) to ($0.58). Immunic posted earnings per share of ($0.82) in the same quarter last year, which […]

Q2 2022 Earnings Estimate for Immunic, Inc. (NASDAQ:IMUX) Issued By Wedbush - Vimarsana News

Q2 2022 Earnings Estimate for Immunic, Inc. (NASDAQ:IMUX) Issued By Wedbush

Immunic, Inc. (NASDAQ:IMUX – Get Rating) – Wedbush raised their Q2 2022 earnings estimates for shares of Immunic in a report issued on Tuesday, May 10th. Wedbush analyst L. Moussatos now anticipates that the company will earn ($0.69) per share for the quarter, up from their prior forecast of ($0.77). Wedbush has a “Outperform” rating […]

Immunic, Inc. Reports First Quarter 2022 Financial Results and Provides Corporate Update - Vimarsana News

Immunic, Inc. Reports First Quarter 2022 Financial Results and Provides Corporate Update

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...

 - Vimarsana News

The following discussion and analysis of financial condition and results of operations should be read in conjunction with our unaudited interim condensed consolidated financial statements and notes... | May 10, 2022

Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease - Vimarsana News

Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...